ten23 health Validates West Synchrony S1 Prefillable Syringe Platform
Following the global launch of the Synchrony S1 PFS system, ten23 health has completed robustness testing to ensure the platform is ready for clients navigating the complexities of drug-device regulations.
Swiss-based CDMO, ten23 health, has announced the successful test and implementation of the West Synchrony S1 prefillable syringe (PFS) system on its fill/finish manufacturing lines. With this early evaluation of the container system, ten23 health can offer the platform to its biopharma customers across clinical and early commercial programs to help them reduce technical risk and accelerate development timelines (1).
The West Synchrony S1 is a prefillable syringe system (PFS) supplied as a ready-to-use container for injectable medicines, available as 1 mL and 2.25 mL staked‑needle options for biologics and 1 mL staked‑needle and Luer‑lock systems for vaccines. The system combines the syringe barrel, plunger, and needle shield/tip cap into one verified system that can be further configured with high-performance NovaPure and FluroTec film laminated plunger components (2).
Evaluation of the Synchrony S1 on its fill/finish lines allows ten23 health to streamline the path from development to clinical supply, and support biopharma clients sooner in the commercial lifecycle. The CDMO’s tests focused on manufacturability, component compatibility, and process robustness under representative sterile conditions, aligning with increasing regulatory expectations for early alignment between container systems and commercial manufacturing processes.
“Having already implemented and tested the West Synchrony S1 prefillable syringe system on our equipment, we are well positioned to support our partners with operational readiness,” said Hanns-Christian Mahler, Chief Enablement Officer, ten23 health, in a company press release about the collaboration (1). “Early hands-on experience with new container systems is critical for de-risking development, particularly as combination products and home-based administration continue to grow.”
Established as a human‑centric and sustainable CDMO, ten23 health operates development and fill/finish facilities in Switzerland with commercial presence in the U.S. and offices in Tokyo. A certified B Corp backed, the company positions itself as a long‑term partner for biopharma and biotech firms seeking to scale injectable products from early development through to commercial supply.
West Pharmaceutical Services’ Synchrony S1 PFS system was made commercially available globally at Pharmapack in January 2026. "As a market leader, West closely monitors shifts in the global drug pipeline by emerging companies, particularly the growing demand for combination products alongside the movement of care from hospital to home, both of which introduce new complexity into regulatory and development processes,” explained Stacey Vaughan, Vice President, Marketing and Portfolio Management at West in a press release about the commercial availability (3). “This surge of innovation across the industry further highlights why now is the right time to introduce West Synchrony S1 prefillable syringe system.”
References
ten23 health. ten23 health and West Collaborate to Ensure Manufacturing Readiness for West Synchrony S1 Prefillable Syringe System Filling. Press Release, May 4, 2026.
West Pharma. West Synchrony S1 Prefillable Syringe System. Westpharma.com (accessed May 7, 2026).
West Pharmaceutical Services. West Synchrony S1 Prefillable Syringe System Commercially Available at Pharmapack. Press Release, Jan. 20, 2026.